Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neurogene Inc.NLTX · Entity 5160 | Director | June 08, 2023 | June 09, 2023 |
| Xencor IncXNCR · Entity 4487 | Director | June 16, 2026 | July 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neurogene Inc.
Report date June 08, 2023 · Filed June 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.79 · Expires 2033-06-07 | Direct | 25,000 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests as to 1/12 of the total shares monthly beginning July 8, 2023 until the option is fully vested on June 8, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 1/12 of the total shares monthly beginning July 8, 2023 until the option is fully vested on June 8, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Xencor Inc
Report date June 16, 2026 · Filed July 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,988 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 10,302 · Balance 23,988 F1: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.20 · Expires 2036-06-15 | Direct | 20,604 |
Reported balance
After 2026-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-16 · Grant · Acquired 20,604 · Balance 20,604 F2: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 16, 2026, such that the total number of shares will be fully vested on June 16, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant.
F2: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 16, 2026, such that the total number of shares will be fully vested on June 16, 2027.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Seagen Inc.
Report date December 14, 2023 · Filed December 15, 2023
Section 16 reporting ended · disclosed 2023-12-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 1
1 source rowRow 1 · 2023-12-14 · Disposition to issuer · Disposed 93,292 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration"). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.86 · Expires 2028-08-30 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-12-14 · Disposition to issuer · Disposed 1,301 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.86 · Expires 2028-08-30 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-12-14 · Disposition to issuer · Disposed 47,904 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.64 · Expires 2029-08-30 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-12-14 · Disposition to issuer · Disposed 1,333 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.64 · Expires 2029-08-30 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-12-14 · Disposition to issuer · Disposed 49,232 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $161.82 · Expires 2030-08-17 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-12-14 · Disposition to issuer · Disposed 636 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $161.82 · Expires 2030-08-17 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-12-14 · Disposition to issuer · Disposed 20,774 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $155.87 · Expires 2031-08-16 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-12-14 · Disposition to issuer · Disposed 642 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $155.87 · Expires 2031-08-16 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-12-14 · Disposition to issuer · Disposed 26,427 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.20 · Expires 2026-05-09 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-12-14 · Disposition to issuer · Disposed 10,526 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-12-14 · Disposition to issuer · Disposed 2,158 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-12-14 · Disposition to issuer · Disposed 5,547 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2023-12-14 · Disposition to issuer · Disposed 11,585 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2023-12-14 · Disposition to issuer · Disposed 1,395 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2023-12-14 · Disposition to issuer · Disposed 14,746 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2023-12-14 · Disposition to issuer · Disposed 3,276 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2023-12-14 · Disposition to issuer · Disposed 4,120 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2023-12-14 · Disposition to issuer · Disposed 656 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2023-12-14 · Disposition to issuer · Disposed 6,666 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2023-12-14 · Disposition to issuer · Disposed 11,400 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2023-12-14 · Disposition to issuer · Disposed 14,251 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2023-12-14 · Disposition to issuer · Disposed 1,639 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · 2023-12-14 · Disposition to issuer · Disposed 983 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · 2023-12-14 · Disposition to issuer · Disposed 1,827 · Balance 0 F7: Pursuant to the Merger Agreement, at the Effective Time, each outstanding "Company Products PSU" (as defined in the Merger Agreement) that was unvested as of immediately prior to the Effective Time was cancelled and converted into the right to receive a Parent cash-based award subject to the same performance-based vesting requirements with respect to an amount in cash that is equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company Products PSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 25
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 25 · 2023-12-14 · Disposition to issuer · Disposed 1,310 · Balance 0 F8: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a "Company August 2023 PSU") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 26
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 26 · 2023-12-14 · Disposition to issuer · Disposed 3,276 · Balance 0 F8: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a "Company August 2023 PSU") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 27
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 27 · 2023-12-14 · Disposition to issuer · Disposed 1,966 · Balance 0 F8: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a "Company August 2023 PSU") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").
F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration").
F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU.
F5: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU.
F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance.
F7: Pursuant to the Merger Agreement, at the Effective Time, each outstanding "Company Products PSU" (as defined in the Merger Agreement) that was unvested as of immediately prior to the Effective Time was cancelled and converted into the right to receive a Parent cash-based award subject to the same performance-based vesting requirements with respect to an amount in cash that is equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company Products PSU.
F8: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a "Company August 2023 PSU") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2020 Filed Aug 5, 2020 19:14 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 1,905 | $166.74 | $317,639.70 |
DisclosureSEC source: 0001203311-20-000069 · edgardoc.xml · nonDerivative · entry 3 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,181 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $166.55 to $166.78. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 19:14 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 10,375 | $166.10 | $1,723,287.50 |
DisclosureSEC source: 0001203311-20-000069 · edgardoc.xml · nonDerivative · entry 2 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,086 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $165.55 to $166.54. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 19:14 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 7,720 | $164.96 | $1,273,491.20 |
DisclosureSEC source: 0001203311-20-000069 · edgardoc.xml · nonDerivative · entry 1 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,461 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $164.55 to $165.548. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 19:19 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 1,010 | $171.39 | $173,103.90 |
DisclosureSEC source: 0000899243-20-018358 · doc4.xml · nonDerivative · entry 5 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,181 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $171.25 to $172.10. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Includes 866 ESPP shares previously reported. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 19:19 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 139 | $170.18 | $23,655.02 |
DisclosureSEC source: 0000899243-20-018358 · doc4.xml · nonDerivative · entry 4 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,191 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Includes 866 ESPP shares previously reported. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 19:19 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 5,012 | $167.66 | $840,311.92 |
DisclosureSEC source: 0000899243-20-018358 · doc4.xml · nonDerivative · entry 3 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,330 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $167.51 to $168.05. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Includes 866 ESPP shares previously reported. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 19:19 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 4,112 | $166.99 | $686,662.88 |
DisclosureSEC source: 0000899243-20-018358 · doc4.xml · nonDerivative · entry 2 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,342 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $166.49 to $167.44. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Includes 866 ESPP shares previously reported. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 19:19 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 1,300 | $165.86 | $215,618.00 |
DisclosureSEC source: 0000899243-20-018358 · doc4.xml · nonDerivative · entry 1 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,454 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $165.37 to $166.28. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Includes 866 ESPP shares previously reported. Read SEC document |
| May 05, 2020 Filed May 6, 2020 18:32 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 26,867 | $0.00 Strike: $15.46 | $0.00 |
DisclosureSEC source: 0001203311-20-000020 · edgardoc.xml · derivative · entry 18 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,867 shares Expires 2021-08-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Options vested at a rate of 25% on 8/24/12 and monthly thereafter until all the shares were fully vested on 8/24/15. Read SEC document |
| May 05, 2020 Filed May 6, 2020 18:32 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,103 | $0.00 Strike: $45.30 | $0.00 |
DisclosureSEC source: 0001203311-20-000020 · edgardoc.xml · derivative · entry 16 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,103 shares Expires 2026-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Options vested at a rate of 25% on 8/27/17 and then monthly thereafter. All the shares shall be fully vested on 8/27/20. Read SEC document |
| May 05, 2020 Filed May 6, 2020 18:32 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,268 | $0.00 Strike: $44.09 | $0.00 |
DisclosureSEC source: 0001203311-20-000020 · edgardoc.xml · derivative · entry 15 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,268 shares Expires 2024-08-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Options vested at a rate of 25% on 8/26/15 and monthly thereafter until all the shares were fully vested on 8/26/18. Read SEC document |
| May 05, 2020 Filed May 6, 2020 18:32 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,436 | $0.00 Strike: $41.04 | $0.00 |
DisclosureSEC source: 0001203311-20-000020 · edgardoc.xml · derivative · entry 14 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,436 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Options vested at a rate of 25% on 8/19/14 and monthly thereafter until all the shares were fully vested on 8/19/17. Read SEC document |
| May 05, 2020 Filed May 6, 2020 18:32 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,554 | $0.00 Strike: $39.15 | $0.00 |
DisclosureSEC source: 0001203311-20-000020 · edgardoc.xml · derivative · entry 13 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,554 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Options vested at a rate of 25% on 8/25/16 and monthly thereafter until all the shares were fully vested on 8/25/19. Read SEC document |
| May 05, 2020 Filed May 6, 2020 18:32 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 3,831 | $0.00 Strike: $26.10 | $0.00 |
DisclosureSEC source: 0001203311-20-000020 · edgardoc.xml · derivative · entry 12 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,831 shares Expires 2022-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the shares were fully vested on 8/20/16. Read SEC document |
| May 05, 2020 Filed May 6, 2020 18:32 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 3,831 | $26.10 | $99,989.10 |
DisclosureSEC source: 0001203311-20-000020 · edgardoc.xml · nonDerivative · entry 11 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| May 05, 2020 Filed May 6, 2020 18:32 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 2,436 | $41.04 | $99,973.44 |
DisclosureSEC source: 0001203311-20-000020 · edgardoc.xml · nonDerivative · entry 10 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 6, 2020 18:32 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 2,268 | $44.09 | $99,996.12 |
DisclosureSEC source: 0001203311-20-000020 · edgardoc.xml · nonDerivative · entry 9 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 6, 2020 18:32 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 2,554 | $39.15 | $99,989.10 |
DisclosureSEC source: 0001203311-20-000020 · edgardoc.xml · nonDerivative · entry 8 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 6, 2020 18:32 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 1,103 | $45.30 | $49,965.90 |
DisclosureSEC source: 0001203311-20-000020 · edgardoc.xml · nonDerivative · entry 7 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,799 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 6, 2020 18:32 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 1,200 | $164.10 | $196,920.00 |
DisclosureSEC source: 0001203311-20-000020 · edgardoc.xml · nonDerivative · entry 6 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,696 F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $164.00 to $164.18. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| May 05, 2020 Filed May 6, 2020 18:32 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 12,167 | $163.36 | $1,987,601.12 |
DisclosureSEC source: 0001203311-20-000020 · edgardoc.xml · nonDerivative · entry 5 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,896 F3 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $163.00 to $163.93. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| May 05, 2020 Filed May 6, 2020 18:32 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 13,500 | $162.45 | $2,193,075.00 |
DisclosureSEC source: 0001203311-20-000020 · edgardoc.xml · nonDerivative · entry 4 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,063 F2 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $162.00 to $162.99. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| May 05, 2020 Filed May 6, 2020 18:32 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 26,867 | $15.46 | $415,363.82 |
DisclosureSEC source: 0001203311-20-000020 · edgardoc.xml · nonDerivative · entry 3 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 7, 2020 20:27 UTC | Neurogene Inc. NLTX · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $12.84 | $0.00 |
DisclosureSEC source: 0001209191-20-027689 · doc4.xml · derivative · entry 1 SIMPSON TODD E · CIK 0001216477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-05-05 F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning June 5, 2020 until the option is fully vested on May 5, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 04, 2020 Filed May 6, 2020 18:32 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 14,167 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0001203311-20-000020 · edgardoc.xml · derivative · entry 17 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,167 shares Expires 2020-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Options vested at a rate of 25% on 8/27/11 and monthly thereafter until all the shares were fully vested on 8/27/14. Read SEC document |
| May 04, 2020 Filed May 6, 2020 18:32 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 14,167 | $147.00 | $2,082,556.08 |
DisclosureSEC source: 0001203311-20-000020 · edgardoc.xml · nonDerivative · entry 2 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,696 F1 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $147.00 to $147.06. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| May 04, 2020 Filed May 6, 2020 18:32 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 14,167 | $12.00 | $170,004.00 |
DisclosureSEC source: 0001203311-20-000020 · edgardoc.xml · nonDerivative · entry 1 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2020 Filed Apr 21, 2020 21:57 UTC | Seagen Inc. SGEN · Entity 13956 | Disposition to issuerCommon Stock | 570 | $139.92 | $79,752.29 |
DisclosureSEC source: 0000899243-20-011114 · doc4.xml · nonDerivative · entry 3 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,696 F4 · shares: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F5 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| April 19, 2020 Filed Apr 21, 2020 21:57 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 1,439 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-011114 · doc4.xml · nonDerivative · entry 2 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,266 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F2 · shares: The performance criteria for these restricted stock units were met. These restricted stock units will become fully vested on 4/19/2022, subject to continuous service with the Company until the vesting date. Read SEC document |
| April 19, 2020 Filed Apr 21, 2020 21:57 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 2,389 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-011114 · doc4.xml · nonDerivative · entry 1 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,827 F3 · shares: The performance criteria for these restricted stock units were met. These restricted stock units became fully vested on 4/19/2020. Read SEC document |
| December 19, 2019 Filed Dec 23, 2019 17:27 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 871 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-029973 · doc4.xml · nonDerivative · entry 1 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,438 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F2 · date: The performance criteria for these restricted stock units were met. These restricted stock units will become fully vested on 12/18/2021, subject to continuous service with the Company until the vesting date. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| October 10, 2019 Filed Oct 15, 2019 20:48 UTC | Neurogene Inc. NLTX · Entity 5160 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0000899243-19-025575 · doc4.xml · derivative · entry 1 SIMPSON TODD E · CIK 0001216477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-10-09 F1 · derivative.exercise_date: The options will vest as to 1/3 of the total number of shares underlying the options on each of October 10, 2020, October 10, 2021 and October 10, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 18:12 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 15,000 | $85.00 | $1,275,000.00 |
DisclosureSEC source: 0001203311-19-000051 · edgardoc.xml · nonDerivative · entry 1 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,567 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 21:42 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 2,092 | $70.80 | $148,112.14 |
DisclosureSEC source: 0000899243-19-022785 · doc4.xml · nonDerivative · entry 2 SIMPSON TODD E · CIK 0001216477 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,567 F4 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 21:42 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 49,232 | $0.00 Strike: $72.64 | $0.00 |
DisclosureSEC source: 0000899243-19-022785 · doc4.xml · derivative · entry 4 SIMPSON TODD E · CIK 0001216477 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,232 Underlying: Common Stock · 49,232 shares Expires 2029-08-30 F5 · derivative.exercise_date: Options shall vest at a rate of 25% one year from grant date and monthly thereafter until all shares are fully vested four years from grant date. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 21:42 UTC | Seagen Inc. SGEN · Entity 13956 | GrantIncentive Stock Option (right to buy) · Derivative | 1,333 | $0.00 Strike: $72.64 | $0.00 |
DisclosureSEC source: 0000899243-19-022785 · doc4.xml · derivative · entry 3 SIMPSON TODD E · CIK 0001216477 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,333 Underlying: Common Stock · 1,333 shares Expires 2029-08-30 F5 · derivative.exercise_date: Options shall vest at a rate of 25% one year from grant date and monthly thereafter until all shares are fully vested four years from grant date. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 21:42 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 21,288 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-022785 · doc4.xml · nonDerivative · entry 1 SIMPSON TODD E · CIK 0001216477 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,659 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F2 · date: Shares shall vest at a rate of 25% on each anniversary of the grant date until all shares are fully vested four years from the grant date. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 28, 2019 Filed Aug 30, 2019 16:36 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 5,909 | $73.21 | $432,623.89 |
DisclosureSEC source: 0001203311-19-000042 · edgardoc.xml · nonDerivative · entry 1 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,371 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 17:49 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 12,500 | $80.00 | $1,000,000.00 |
DisclosureSEC source: 0001203311-19-000034 · edgardoc.xml · nonDerivative · entry 1 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,280 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| April 05, 2019 Filed Apr 9, 2019 20:35 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 10,437 | $78.00 | $814,086.00 |
DisclosureSEC source: 0000899243-19-010414 · doc4.xml · nonDerivative · entry 2 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,780 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| April 05, 2019 Filed Apr 9, 2019 20:35 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 2,063 | $78.00 | $160,914.00 |
DisclosureSEC source: 0000899243-19-010414 · doc4.xml · nonDerivative · entry 1 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,217 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 18:58 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 10,000 | $75.00 | $750,000.00 |
DisclosureSEC source: 0001203311-19-000006 · edgardoc.xml · nonDerivative · entry 1 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,280 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting and 359 shares acquired under the Amended and Restated 2000 Employee Stock Purchase Plan on January 31, 2019. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 20:58 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 47,904 | $0.00 Strike: $76.86 | $0.00 |
DisclosureSEC source: 0001203311-18-000081 · edgardoc.xml · derivative · entry 3 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,904 Underlying: Common Stock · 47,904 shares Expires 2028-08-30 F4 · derivative.exercise_date: Shares shall vest at a rate of 25% one year from the grant date and monthly thereafter until all shares are fully vested four years from the grant date. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 20:58 UTC | Seagen Inc. SGEN · Entity 13956 | GrantIncentive Stock Option (right to buy) · Derivative | 1,301 | $0.00 Strike: $76.86 | $0.00 |
DisclosureSEC source: 0001203311-18-000081 · edgardoc.xml · derivative · entry 2 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,301 Underlying: Common Stock · 1,301 shares Expires 2028-08-30 F4 · derivative.exercise_date: Shares shall vest at a rate of 25% one year from the grant date and monthly thereafter until all shares are fully vested four years from the grant date. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 20:58 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 20,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001203311-18-000081 · edgardoc.xml · nonDerivative · entry 1 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,280 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F2 · date: Shares shall vest at a rate of 25% on each anniversary of the grant date until all shares are fully vested four years from the grant date. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 19:40 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 5,427 | $74.23 | $402,855.98 |
DisclosureSEC source: 0001203311-18-000069 · edgardoc.xml · nonDerivative · entry 1 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,565 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| May 07, 2018 Filed May 9, 2018 22:19 UTC | Neurogene Inc. AQXP · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $13.10 | $0.00 |
DisclosureSEC source: 0001209191-18-028988 · doc4.xml · derivative · entry 1 SIMPSON TODD E · CIK 0001216477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-05-06 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 1/12th of the total number of shares underlying the options on the one-month anniversary of May 7, 2018 (the "Vesting Commencement Date") and 1/12th of the total number of shares underlying the options each monthly anniversary of the Vesting Commencement Date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the one-year anniversary of the Vesting Commencement Date. Read SEC document |
| March 20, 2018 Filed Mar 22, 2018 21:32 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-qualified Stock Option (Right to buy) · Derivative | 10,526 | $0.00 Strike: $34.20 | $0.00 |
DisclosureSEC source: 0000899243-18-008413 · doc4.xml · derivative · entry 1 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,526 Underlying: Common Stock · 10,526 shares Expires 2026-05-09 F1 · derivative.exercise_date: On May 9, 2016, the reporting person was granted an option to purchase 10,526 options of common stock. The performance criteria for this grant were met as of March 20, 2018 and the option shall vest in four (4) equal tranches on the first, second, third and fourth anniversaries of March 20, 2018 subject to continuous service with the Company as of each vesting date. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 17:42 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 534 | $61.59 | $32,889.06 |
DisclosureSEC source: 0001203311-17-000086 · edgardoc.xml · nonDerivative · entry 2 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,992 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 17:42 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 38,851 | $60.90 | $2,366,025.90 |
DisclosureSEC source: 0001203311-17-000086 · edgardoc.xml · nonDerivative · entry 1 SIMPSON TODD E · CIK 0001216477 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,526 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: Table 1, Col 4, Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $60.51 to $61.35 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.